William Blair Reiterates “Outperform” Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY)

William Blair reiterated their outperform rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research report report published on Tuesday,RTT News reports.

Other analysts have also recently issued research reports about the stock. Wolfe Research cut shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a report on Tuesday, November 12th. Chardan Capital reaffirmed a “buy” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. Bank of America lifted their target price on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a report on Monday, October 14th. Canaccord Genuity Group lifted their target price on shares of Alnylam Pharmaceuticals from $366.00 to $384.00 and gave the company a “buy” rating in a report on Friday, November 1st. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $298.09.

Alnylam Pharmaceuticals Stock Down 0.8 %

ALNY stock opened at $244.89 on Tuesday. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals has a twelve month low of $141.98 and a twelve month high of $304.39. The company’s 50 day moving average is $273.54 and its two-hundred day moving average is $236.84. The stock has a market cap of $31.59 billion, a P/E ratio of -93.35 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. During the same quarter in the prior year, the firm posted $1.15 earnings per share. The company’s quarterly revenue was down 33.3% compared to the same quarter last year. Research analysts expect that Alnylam Pharmaceuticals will post -2.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Teachers Retirement System of The State of Kentucky boosted its position in shares of Alnylam Pharmaceuticals by 4.5% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 34,713 shares of the biopharmaceutical company’s stock worth $9,547,000 after purchasing an additional 1,500 shares in the last quarter. Toronto Dominion Bank boosted its position in shares of Alnylam Pharmaceuticals by 27.3% during the 3rd quarter. Toronto Dominion Bank now owns 15,466 shares of the biopharmaceutical company’s stock worth $4,254,000 after purchasing an additional 3,315 shares in the last quarter. Coldstream Capital Management Inc. boosted its position in shares of Alnylam Pharmaceuticals by 43.7% in the 3rd quarter. Coldstream Capital Management Inc. now owns 1,211 shares of the biopharmaceutical company’s stock worth $329,000 after buying an additional 368 shares in the last quarter. Geode Capital Management LLC grew its stake in Alnylam Pharmaceuticals by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock valued at $589,209,000 after acquiring an additional 66,928 shares during the last quarter. Finally, Prestige Wealth Management Group LLC grew its stake in Alnylam Pharmaceuticals by 65.8% in the 3rd quarter. Prestige Wealth Management Group LLC now owns 451 shares of the biopharmaceutical company’s stock valued at $124,000 after acquiring an additional 179 shares during the last quarter. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.